London · Delayed Price · Currency is GBP · Price in GBX Thalia Therapeutics Company Description
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.
It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring.
Thalia Therapeutics Plc was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026.
Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1979 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Solomon |
Contact Details
Address: 2 Portman Street London, W1H 6DU United Kingdom | |
| Phone | 44 20 4610 0714 |
| Website | thaliatx.com |
Stock Details
| Ticker Symbol | THAT |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BYW8QM32 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| David Solomon | Chief Executive Officer |